Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H22N2O |
Molecular Weight | 246.348 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCCN3CCC[C@]([H])([C@@]4([H])CC=CC(=O)N4C1)[C@]23[H]
InChI
InChIKey=AAGFPTSOPGCENQ-JLNYLFASSA-N
InChI=1S/C15H22N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h1,7,11-13,15H,2-6,8-10H2/t11-,12+,13+,15-/m0/s1
Molecular Formula | C15H22N2O |
Molecular Weight | 246.348 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: doi: 10.1248/cpb.13.482Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/24587659 | https://www.ncbi.nlm.nih.gov/pubmed/23395669 | https://www.ncbi.nlm.nih.gov/pubmed/18379053
Sources: doi: 10.1248/cpb.13.482
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/24587659 | https://www.ncbi.nlm.nih.gov/pubmed/23395669 | https://www.ncbi.nlm.nih.gov/pubmed/18379053
Sophocarpine is a dehydrogenation derivative of the bis-quinolizidine alkaloid matrine. Sophocarpine is also an active component in sophora alkaloids, which possess a variety of pharmacological effects such as anti-inflammation, immunity regulation, antivirus, and anti-tumor actions. Sophocarpine is able to block HERG K+ channel. It is Na+ channel inward current inhibitor. It activates the AMPK signaling pathway and inhibits the TLR4-downstream pathway.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18379053 |
100.0 µM [IC50] | ||
Target ID: map04152 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23395669 |
|||
Target ID: Sodium channel Sources: https://www.ncbi.nlm.nih.gov/pubmed/23064241 |
|||
Target ID: TLR4 signaling pathway |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Mechanism of sophocarpine in treating experimental colitis in mice]. | 2015 Aug |
|
Inhibition of Sophocarpine on Poly I: C/D-GalN-Induced Immunological Liver Injury in Mice. | 2016 |
|
RETRACTED: Sophocarpine displays anti-inflammatory effect via inhibiting TLR4 and TLR4 downstream pathways on LPS-induced mastitis in the mammary gland of mice. | 2016 Jun |
|
Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT with sophocarpine. | 2016 Jun 28 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24587659
Rat: 20 mg/kg once a day
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23064241
In the presence of ATX II, SOP (20, 40, and 80 mM) reversed the increased INa.L in a concentration-dependent manner.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:22:08 GMT 2023
by
admin
on
Sat Dec 16 09:22:08 GMT 2023
|
Record UNII |
X9X8U6P2NP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
X9X8U6P2NP
Created by
admin on Sat Dec 16 09:22:08 GMT 2023 , Edited by admin on Sat Dec 16 09:22:08 GMT 2023
|
PRIMARY | |||
|
DTXSID90215126
Created by
admin on Sat Dec 16 09:22:08 GMT 2023 , Edited by admin on Sat Dec 16 09:22:08 GMT 2023
|
PRIMARY | |||
|
115269
Created by
admin on Sat Dec 16 09:22:08 GMT 2023 , Edited by admin on Sat Dec 16 09:22:08 GMT 2023
|
PRIMARY | |||
|
6483-15-4
Created by
admin on Sat Dec 16 09:22:08 GMT 2023 , Edited by admin on Sat Dec 16 09:22:08 GMT 2023
|
PRIMARY |